The company is also recalling another lot of sapropterin dihydrochloride for the same reason, it added. The USFDA said the drug maker initiated the Class I recall in the US on April 8 this year. As per the US health regulator, a Class I recall pertains to defective products that can cause serious health problems ..read more

India's pharma market took a dip in March after poor sales of respiratory and anti-infective therapies dropped post-winter. April saw the market bounce back with 9% growth year-on-year, on the back of gastroenterology medicines, Pan and Pan D, which increased sales by 19% and 17% respectively, liver therapies, Liv-52 by 17%, and Udiliv 28 ..read more

SII said, in a statement on Friday that the partnership with IntegriMedical aligns with its vision of 'Health for All' and IntegriMedical's mission to 'transform healthcare globally' by providing patient comfort, ensuring increased patient compliance, reducing needle-stick injuries, and enhancing the efficacy of liquid medication via needle-free dispersion ..read more

India's drug regulator has directed state counterparts to provide a list of antibiotic combinations licensed for manufacturing and marketing within two weeks to combat misuse. This move follows recommendations from an expert sub-committee under the Drugs Technical Authority Board (DTAB) to regulate antibiotic use. The regulator seeks to ban inappropriate combinations and monitor unapproved antibiotics in the market. A sub-committee was formed to examine this issue, leading to the recent directive to state drug regulators and port officers ..read more

The government mandates companies to carry out post-market surveillance (PMS) of medical devices with an aim to ensure the safety and performance of the devices ..read more

The Vadodara-based drug maker, which has been around for over a century, is a late entrant in the US market. It has more than made up for it. It has been on an investment overdrive, spending about ₹700-₹750 crore per annum on R&D to build a complex pipeline of products for the US market ..read more

AstraZeneca's COVID-19 prevention therapy, sipavibart, has shown a significant reduction in symptomatic COVID-19 cases among immunocompromised patients, a group comprising about 25% of COVID-19 hospitalizations, ICU admissions, and deaths. The therapy, acquired from RQ Bio in May 2022, is expected to work with regulatory authorities globally to bring sipavibart to these vulnerable patients ..read more

Cipla has announced further investment of up to Rs 26 crore in Achira Labs, a company specializing in point-of-care medical test kits. This investment will be made in four tranches, contingent upon the achievement of specific milestones. After the first tranche, Cipla will hold 27.27% of the total voting rights in Achira. This decision follows Cipla's initial acquisition of a 21.05% stake in Achira Labs in June 2022. Achira Labs, based in Bengaluru, focuses on developing and commercializing regulatory-approved medical diagnostic products using microfluidic technology ..read more

The move, days after the company posted its best annual results, has triggered speculation that more such transactions could be in the offing. The collapse of the $7 billion sale last year after lengthy negotiations had reportedly led to divisions within the family, according to people with knowledge of the matter ..read more

Biocon partners with Medix to distribute Liraglutide for chronic weight management in Mexico, offering affordable obesity treatment options. The collaboration aims to improve patient access and quality of life in a country with high obesity rates ..read more